A red-faced BioCryst Pharmaceuticals Inc. announced that an incorrect randomization key is responsible for Phase II data that were erroneously reported in February to be statistically significant.

"Obviously, it's very embarrassing for the company," BCRX Director of Corporate Development John Higgins told BioCentury. However, he said, the development timeline for the BCX-34 skin drug, and the projected expenses as it passes through the pipeline, have not altered.